Australia
OmnigeniQ, founded in 2024, is a pioneering research company that integrates the realms of life sciences, advanced computation, and artificial intelligence. Its origins in space research are noteworthy, having created a bioreactor for the NASA Artemis Program to cultivate pancreatic organoids, facilitating the in-situ production of biologics like insulin for deep space missions.
The company's innovative edge stems from its proprietary platform, developed to model physical forces governing biology through first principles rather than conventional training sets. This platform encompasses four applications designed to predict biological behavior with exceptional accuracy. A landmark achievement was recorded in January 2026 when OmnigeniQ became the first to deterministically fold a protein from its DNA sequence.
Driven by the mission to expedite drug discovery and material innovation, OmnigeniQ focuses on uncovering new drug targets, optimizing underperforming assets, and drastically reducing the time required for discovering new materials across various sectors.
